What BiotechTeen seems to have forgotten is precisely what you point out - that this is an orphan indication and thus we have Orphan status, which incidentally Celebrex doesn't have, and it gives us some patent advantages. I can't begin to guess where this kid does his so-called DD.
A few facts we longs can use to sleep peacefully at night:
1. 85% of NDAs are accepted by the FDA. 2. With Orphan status and clear safety and efficacy data, the odds will be considerably better than that. 3. After approval, off-label revenues for prostate should be enormous. 4. The sporadic polyp trial finale is just around the corner. That s a 2.6M patient pool that we should get a large bite of. 5. On Monday the clinical trials analysts will begin to crunch the numbers on the PIII prostate trial. If the interim data hold up, and we continue to see a halt in the rise of PSA, that's a wow. If the data show reduction, that would leave me breathless... 6. The shorts have knocked the price down to rediculous levels. Now that the APC trial results are out, institutions will begin to buy once they have had their meetings.
Of course none of this addresses the future potential, which is stratospheric. Lung and breast cancer, combination therapy with taxanes, etc. Let's be a little grateful to the shorts, as they have given us a gift of sorts... Once Wall Street wakes up, we'll be in for a heck of a ride...
I had to go back to see how I "attack" you because at my age one forgets. You didn't answer the question, why do you spend time here? I'm over the hill with little else to do so that's part of reason I'm here. Have you met Mr Fuelcell yet @ MKTY? I thought you were 2 peas in a pod,now I Think different.While objectionable he KNOWS his stuff. Cheers Lou